학술논문
IBCL-460 Subcutaneous Epcoritamab With Rituximab + Lenalidomide (R2) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Update from Phase 1/2 Trial
Document Type
Article
Author
Source
In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S392-S392
Subject
Language
ISSN
2152-2650